Guidelines on the management of Waldenström macroglobulinaemia

British Journal of Haematology

Volumn 132, Issue 6, 2006, Pages 683-697

  Johnson, S A ^a   Birchall, J ^b   Luckie, C ^c   Oscier, D G ^d   Owen, R G ^e  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UK Waldenström Macroglobulinaemia Support Group   (United Kingdom)

^d POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Diagnosis; Treatment; Waldenstr m macroglobulinaemia

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BORTEZOMIB; CD20 ANTIBODY; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; MELPHALAN; MONOCLONAL ANTIBODY; OBLIMERSEN; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; CRYOGLOBULINEMIA; CYTOPENIA; DIAGNOSTIC PROCEDURE; DRUG MEGADOSE; EMBASE; EYE DISEASE; HUMAN; HYPERVISCOSITY SYNDROME; LYMPHOMA; MEDLINE; MYELODYSPLASIA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; CLADRIBINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; PROGNOSIS; STEM CELL TRANSPLANTATION; THALIDOMIDE; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 33644923231     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05948.x     Document Type: Review

References (110)

1. Ackroyd S. O'Connor S.J. Owen R.G. 2005a Rarity of IgH translocations in Waldenstrom's macroglobulinaemia Cancer Genetics and Cytogenetics 163 77 80
2. Ackroyd S. O'Connor S.J. Rawstron A.C. Owen R.G. 2005b IgM myeloma with t(4;14)(p16;q32) Cancer Genetics and Cytogenetics 162 183 184
3. Anagnostopoulos A. Dimopoulos M.A. Aleman A. Weber D. Alexanian R. Champlin R. Giralt S. 2001 High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia Bone Marrow Transplantation 27 1027 1029
4. Anagnostopoulos A. Aleman A. Giralt S. 2003 Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions Seminars in Oncology 30 286 290
5. Annibali O. Petrucci M.T. Martini V. Tirindelli M.C. Levi A. Fossati C. Del Bianco P. Mandelli F. Foa R. Avvisati G. 2005 Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide and prednisone: results and cost analysis Cancer 103 582 587
6. Avet-Loiseau H. Garand R. Lode L. Harousseau J.L. Bataille R. 2003a Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE and nonsecretory multiple myeloma variants Blood 101 1570 1571
7. Avet-Loiseau H. Garand R. Lode L. Robillard R. Bataille R. 2003b 14q32 translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia Seminars in Oncology 30 153 155
8. Avnstorp C. Nielsen H. Drachmann O. Hippe E. 1985 Plasmapheresis in hyperviscosity syndrome Acta Medica Scandinavica 217 133 137
9. Bartl R. Frisch B. Mahl G. Burkhardt R. Fateh-Moghadam A. Pappenberger R. Sommerfeld W. Hoffman-Fezer G. 1983 Bone marrow histology in Waldenstrom's macroglobulinaemia Scandinavian Journal of Haematology 31 359 375
10. Betticher D.C. Hsu Schmitz S.F. Ratschiller D. von Rohr A. Egger T. Pugin P. Stalder M. Hess U. Fey M.F. Cerny T. 1997 Cladribine (2-CDA) given as subcutaneous bolus injections is active in pre-treated Waldenström's macroglobulinaemia British Journal of Haematology 99 358 363
11. Buskard N.A. Galton D.A.G. Goldman J.M. Kohner E.M. Grindle C.F.J. Newman D.L. Twinn K.W. Lowenthal R.M. 1977 Plasma exchange in the long-term management of Waldenström's macroglobulinemia Canadian Medical Association Journal 117 135 137
12. Busnach G. Perrino M.L. Dal Col A. Brando B. Minetti L. 1983 Removal and recovery rate of paraproteins by plasma exchange Life Support Systems 1 Suppl. 1 112 114
13. Byrd J.C. White C.A. Link B. Lucas M.S. Velasquez W.S. Rosenberg J. Grillo-Lopez A.J. 1999 Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity Annals of Oncology 10 1525 1527
14. Case D.C. Ervin T.J. Boyd M.A. Redfield D.L. 1991 Waldenström's macroglobulinemia: long term results with the M-2 protocol Cancer Investigation 9 1 7
15. Coleman M. Leonard J. Lyons L. Szelenyi H. Niesvizky R 2003 Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone Seminars in Oncology 30 270 274
16. Del Guidice I. Matutes E. Osuji N. Parry-Jones N. Swansbury J. Catovsky D. 2005 Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia Haematologica 90 268 270
17. Delannoy A. Van den Neste E. Michaux J.L. Bosly A. Ferrant A. 1999 Cladribine for Waldenström's macroglobulinaemia British Journal of Haematology 104 928 936
18. Desikan R. Dhodapkar M. Siegel D. Fassas A. Singh J. Singhal S. Mehta J. Vesole D. Tricot G. Jagannath S. Anaissie E. Barlogie B. Munshi N.C. 1999 High dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinemia British Journal of Haematology 105 993 996
19. Dhodapkar M.V. Jacobson J.L. Gertz M.A. Crowley J.J. Barlogie B. 2001 Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (South West Oncology Group S9003) Blood 98 41 48
20. Dhodapkar M.V. Jacobson J.L. Gertz M.A. Crowley J.J. Barlogie B. 2003 Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US Intergroup trial (SWOG S9003) Seminars in Oncology 30 220 225
21. Dimopoulos M.A. Alexanian R. 1994 Waldenström's macroglobulinaemia Blood 83 1452 1459
22. Dimopoulos M.A. O'Brien S. Kantarjian H. Pierce S. Delasalle K. Barlogie B. Alexanian R. Keating M.J. 1993a Fludarabine therapy in Waldenström's macroglobulinemia American Journal of Medicine 95 49 52
23. Dimopoulos M.A. Kantarjian H. Estey E. O'Brien S. Delasalle K. Keating M.J. Freireich E.J. Alexanian R. 1993b Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine Annals of Internal Medicine 118 195 198
24. Dimopoulos M.A. Kantarjian H. Weber D. O'Brien S. Estey E. Delasalle K. Rose E. Cabanillas F. Keating M. Alexanian R. 1994a Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine Journal of Clinical Oncology 12 2694 2698
25. Dimopoulos M.A. Weber D.M. Kantarjian H. Keating M. Alexanian R. 1994b 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine Annals of Oncology 5 288 289
26. Dimopoulos M.A. Weber D. Delasalle K.B. Keating M. Alexanian R. 1995 Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors Annals of Oncology 6 49 52
27. Dimopoulos M.A. Panayiotidis P. Moulopoulos L.A. Sfikakis P. Dalakas M. 2000 Waldenstrom's macroglobulinemia: clinical features, complications, and management Journal of Clinical Oncology 18 214 226
28. Dimopoulos M.A. Zomas A. Viniou N.A. Grigoraki V. Galani E. Matsouka C. Economou O. Anagnostopoulos N. Panayiotidis P. 2001 Treatment of Waldenstrom's macroglobulinaemia with thalidomide Journal of Clinical Oncology 19 3596 3601
29. Dimopoulos M.A. Zervas C. Zomas A. Hamilos G. Gika D. Efstathiou E. Panayiotidis P. Vervessou E. Anagnostopoulos N. Christakis J. 2002a Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia Clinical Lymphoma 3 163 166
30. Dimopoulos M.A. Zomas A. Viniou N.A. Grigoraki V. Galani E. Matsouka C. Economou O. Anagnostopoulos N. Panayiotidis P. 2002b Treatment of Waldenström's macroglobulinemia with rituximab Journal of Clinical Oncology 20 2327 2333
31. Dimopoulos M.A. Hamilos G. Efstathiou E. Siapkaras I. Matsouka C. Gika D. Grigoraki V. Papadimitriou C. Mitsibounas D. Anagnastopoulos N. 2003a Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide Leukemia and Lymphoma 44 993 996
32. Dimopoulos M.A. Tsatalas C. Zomas A. Hamilos G. Panayiotidis P. Margaritis D. Matsouka C. Economopoulos T. Anagnostopoulos N. 2003b Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone Seminars in Oncology 30 265 269
33. Dimopoulos M.A. Anagnostopoulos A. Kyrtsonis M.C. Castritis E. Bitsaktsis A. Pangalis G.A. 2005 Treatment of relapsed or refractory Waldenstrom macroglobulinemia with bortezomib Haematologica 90 1655 1658
34. Dreger P. Glass B. Kuse R. Sonnen R. von Neuhoff N. Bolouri H. Kneba M. Schmitz N. 1999 Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia British Journal of Haematology 106 115 118
35. Drew M.J. 2002 Plasmapheresis in the dysproteinaemias Therapeutic Apheresis 6 45 52
36. Dyck P.J. Low P.A. Windebank A.J. Jaradeh S.S. Gosselin S. Bourque P. Smith B.E. Kratz K.M. Karnes J.L. Evans B.A. Pineda A.A. O'Brien P.C. Kyle R.A. 1991 Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance New England Journal of Medicine 325 1482 1486
37. Ernerudh J. Brodtkorb E. Olsson T. Vedeler C.A. Nyland H. Berlin G. 1986 Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin: effect of plasma exchange Journal of Neuroimmunology 11 171 178
38. Facon T. Brouillard M. Duhamer A. Morel P. Simon M. Bauters F. Fenaux P. 1993 Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases Journal of Clinical Oncology 11 1553 1558
39. Fahey J.L. Barth W.F. Solomon A. 1965 Serum hyperviscosity syndrome Journal of the American Medical Association 192 464 467
40. Foran J.M. Rohatiner A.Z. Coiffier B. Barbui T. Johnson S.A. Hiddemann W. Radford J.A. Norton A.J. Tollerfield S.M. Wilson M.P. Lister T.A. 1999 Multicentre phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinaemia and mantle cell lymphoma Journal of Clinical Oncology 17 546 553
41. Foran J.M. Rohatiner A.Z. Cunningham D. Popescu R.A. Solal-Celigny P. Ghielmini M. Coiffier B. Johnson P.W. Gisselbrecht C. Reyes F. Radford J.A. Bessell E.M. Souleau B. Benzohra A. Lister T.A. 2000 European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma Journal of Clinical Oncology 18 317 324
42. Frankel S.R. 2003 Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis Seminars in Oncology 30 300 304
43. Garcia-Sanz R. Montoto S. Torrequebrada A. de Coca A.G. Petit J. Sureda A. Rodriguez-Garcia J.A. Masso P. Perez-Aliaga A. Monteagudo M.D. Navarro I. Moreno G. Toledo C. Alonso A. Besses C. Besalduch J. Jarque I. Salama P. Rivas J.A. Navarro B. Blade J. San Miguel J.F. 2001 Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases British Journal of Haematology 115 575 582
44. Gertz M.A. Kyle R.A. Noel P. 1993 Primary systemic amyloidosis: a rare complication of immunoglobulin M gammopathies and Waldenstrom's macroglobulinemia Journal of Clinical Oncology 11 914 920
45. Gertz M.A. Rue M. Blood E. Kaminer L.S. Vesole D. Greipp P.R. 2004 Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group study (E3A98) Leukemia and Lymphoma 45 2047 2055
46. Ghobrial I.M. Fonseca R. Greipp P.R. Blod E. Montserrat R. Vesole D.H. Gertz M.A. 2004 Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia Cancer 101 2593 2598
47. Gobbi P.G. Bettini R. Montecucco C. Cavanna L. Morandi S. Pieresca C. Merlini G. Bertoloni D. Grignani G. Pozzetti U. Caporali R. Ascari E. 1994 Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility Blood 83 2939 2945
48. Haas D.C. Tatum A.H. 1988 Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinaemia Annals of Neurology 23 394 396
49. Herrinton L.J. Weiss N.S. 1993 Incidence of Waldenstrom's macroglobulinemia Blood 82 3148 3150
50. Kantarjian H.M. Alexanian R. Koller C.A. Kurzrock R. Keating M.J. 1990 Fludarabine therapy in macroglobulinemic lymphoma Blood 75 1928 1931
51. Kaplan A.A. 2001 Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinaemias Therapeutic Apheresis 5 171 175
52. Koo A.P. 2000 Therapeutic apheresis in autoimmune and rheumatic diseases Journal of Clinical Apheresis 15 18 27
53. Kriangkum J. Taylor B.J. Treon S.P. Mant M.J. Belch A.R. Pilarski L.M. 2004 Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglogulinemia suggest an unusual B-cell origin and an expansion of polyclonal B-cells in peripheral blood Blood 104 2134 2142
54. Krishna V.M. Carey R.W. Bloch K.J. 2003 Marked increase in serum IgM during treatment of Waldenstrom's macroglobulinemia with cladribine New England Journal of Medicine 348 2045 2046
55. Kyle R.A. Rajkumar S.V. 2003 Monoclonal gammopathies of undetermined significance: a review Immunological Reviews 194 112 139
56. Kyle R.A. Greipp P.R. Gertz M.A. Witzig T.E. Lust J.A. Lacy M.Q. Therneau T.M. 2000 Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil British Journal of Haematology 108 737 742
57. Kyle R.A. Treon S.P. Alexanian R. Barlogie B. Bjorkholm M. Dhodapkar M. Lister T.A. Merlini G. Morel P. Stone M. Branagan A.R. Leblond V. 2003 Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemai: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia Seminars in Oncology 30 116 120
58. Lawson N.S. Nosanchuk J.S. Oberman H.A. Meyers M.C. 1968 Therapeutic plasmapheresis in treatment of patients with Waldenstrom's macroglobulinaemia Transfusion 8 174 178
59. Leblond V. Ben-Othman T. Deconinck E. Taksin A.L. Harousseau J.L. Delgado M.A. Delmer A. Maloisel F. Mariette X. Morel P. Clauvel J.P. Duboisset P. Entezam S. Hermine O. Merlet M. Yakoub-Agha I. Guibon O. Caspard H. Fort N. 1998 Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases Journal of Clinical Oncology 16 2060 2064
60. Leblond V. Levy V. Maloisel F. Cazin B. Fermand J.P. Harousseau J.L. Remenieras L. Porcher R. Gardembas M. Marit G. Deconinck E. Desablens B. Guilhot F. Philippe G. Stamatoullas A. Guibon O. 2001 Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide- doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease Blood 98 2640 2644
61. Levy V. Porcher R. Leblond V. Fermand J.P. Cazin B. Maloisel F. Harousseau J.L. Remenieras L. Guibon O. Chevret S. 2001 Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis Leukemia 15 1466 1470
62. Lewandowski K. Zaucha J.M. Bieniaszewska M. Halaburda K. Hellmann A. 2000 2-Chlorodeoxyadenosine treatment of Waldenstrom's macroglobulinemia - the analysis of own experience and the review of literature Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 6 740 745
63. Lewandowski K. Halaburda K. Hellman A. 2002 Fludarabine therapy in Waldenstrom's macroglobulinaemia patients treated previously with 2-chlorodeoxyadenosine Leukemia and Lymphoma 43 361 363
64. Liu E.S. Burian C. Miller W.E. Saven A. 1998 Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia British Journal of Haematology 103 690 695
65. MacKenzie M.R. Brown E. Fudenberg H.H. Goodenday L. 1970 Waldenstrom's macroglobulinaemia: correlation between expanded plasma volume and increased serum viscosity Blood 35 394 408
66. Maloisel F. Campos F. Giron C. Dufour P. 2000 Second treatment with fludarabine in a Waldenstrom's macroglobulinemia patient Leukemia 14 220
67. Martino R. Shah A. Romero P. Brunet S. Sierra J. Domingo-Albos A. Fruchtman S. Isola L. 1999 Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia Bone Marrow Transplantation 23 747 749
68. McGrath M.A. Penny R. 1976 Paraproteinaemia: blood hyperviscosity and clinical manifestations The Journal of Clinical Investigation 58 1155 1162
69. McMaster M.L. 2003 Familial Waldenstrom's macroglobulinemia Seminars in Oncology 30 146 152
70. Merlini G. Baldini L. Broglia C. Comelli M. Goldaniga M. Palladini G. Deliliers G.L. Gobbi P.G. 2003 Prognostic factors in symptomatic Waldenstrom's macroglobulinemia Seminars in Oncology 30 211 215
71. Morel P. Monconduit M. Jacomy D. Lenain P. Grosbois B. Bateli C. Facon T. Dervite I. Bauters F. Najman A. de Gramont A. Wattel E. 2000 Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients Blood 96 852 858
72. Munshi N.C. Barlogie B. 2003 Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia Seminars in Oncology 30 282 285
73. Nichols G.L. Savage D.G. 2004 Timing of rituximab/fludarabine in Waldenstrom's macroglobulinemia may avert hyperviscosity Blood 104 237b
74. Oksenhendler E. Chevret S. Leger J.M. Louboutin J.P. Bussel A. Brouet J.C. 1995 Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated polyneuropathy study group Journal of Neurology, Neurosurgery and Psychiatry 59 243 247
75. Owen R.G. 2003 Developing diagnostic criteria in Waldenstrom's macroglobulinemia Seminars in Oncology 30 196 200
76. Owen R.G. 2004 Monoclonal immunoglobulins and peripheral neuropathy: causative agent or coincidental finding Clinical Lymphoma 5 172 173
77. Owen R.G. Parapia L.A. Higginson J. Misbah S.A. Child J.A. Morgan G.J. Jack A.S. 2000 Clinicopathological correlates of IgM paraproteinemias Clinical Lymphoma 1 39 43
78. Owen R.G. Barrans S.L. Richards S.J. O'Connor S.J.M. Child J.A. Parapia L.A. Morgan G.J. Jack A.S. 2001 Waldenstrom macroglobulinemia: development of diagnostic criteria and identification of prognostic factors American Journal of Clinical Pathology 116 420 428
79. Owen R.G. Treon S.P. Al-Katib A. Fonseca R. Greipp P.R. McMaster M.L. Morra E. Pangalis G.A. San Miguel J.F. Branagan A.R. Dimopoulos M.A. 2003a Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia Seminars in Oncology 30 110 115
80. Owen R.G. Rawstron A.C. Osterborg A. Lundin J. Svensson G. Hillmen P. 2003b Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia Blood 102 644 645a
81. Pestronk A. Florence J. Miller T. Choksi R. Al-Lozi M.T. Levine T.D. 2003 Treatment of IgM antibody associated polyneuropathies using rituximab Journal of Neurology Neurosurgery and Psychiatry 74 485 489
82. Petrucci M.T. Avvisati G. Tribalto M. Giovangrossi P. Mandelli F. 1989 Waldenström's macroglobulinemia: results of a combined oral treatment in 34 newly diagnosed patients Journal of Internal Medicine 226 443 447
83. Phekoo K. Moller H. Richards M. Bell S. Gillett D. Bevan D. Streetly M. Schey S. 2005 Incidence and survival of Waldenström's macroglobulinemia: a population study Haematologica 90 Suppl. 1 198 199
84. Powles R. Smith C. Kohn J. Fairley G.H. 1971 Method of removing abnormal protein rapidly from patients with malignant paraproteinaemias British Medical Journal 3 664 667
85. Reinhart W.H. Lutolf O. Nydegger U. Mahler F. Straub P.W. 1992 Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation Journal of Laboratory and Clinical Medicine 119 69 76
86. Rollett R.A. Wilkinson E. Gonzalez D. Fenton J.A.L. Short M. Evans P. Owen R.G. 2004 Ig sequence analysis in Waldenstrom's macroglobulinemia and IgM MGUS Blood 104 994a
87. Ropper A.H. Gorson K.C. 1998 Neuropathies associated with paraproteinaemia New England Journal of Medicine 338 1601 1607
88. Rotoli B. De Renzo A. Frigeri F. Buffardi S. Marceno R. Cavallarp A.M. Ruggeri P. Liso V. Musto P. Andriani A. 1994 A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal gammopathy Leukemia and Lymphoma 13 463 469
89. Sahota S.S. Forconi F. Ottensmeier C.H. Provan D. Oscier D.G. Hamblin T.J. Stevenson F.K. 2002 Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events Blood 100 1505 1507
90. San Miguel J.F. Vidriales M.B. Ocio E. Mateo G. Sanchez-Guijo F. Sanchez M.L. Escribano L. Barez A. Moro M.J. Hernandez J. Aguilera C. Cuello R. Garcia-Frade J. Lopez R. Portero J. Orfao A. 2003 Immunophenotypic analysis in Waldenstrom's macroglobulinemia Seminars in Oncology 30 187 195
91. Schop R.F.J. Kuehl W.M. Van Wier S.A. Ahmann G.J. Price-Troska T. Bailey R.J. Jalal S.M. Qi Y. Kyle R.A. Fonseca R. 2002 Waldenstrom's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions Blood 100 2996 3001
92. Schwab P.J. Fahey J.L. 1960 Treatment of Waldenstrom's macroglobulinaemia by plasmapheresis New England Journal of Medicine 263 574 579
93. Simovic D. Gorson K.C. Ropper A.H. 1998 Comparison of IgM-MGUS and IgG-MGUS polyneuropathy Acta Neurologica Scandinavica 97 194 200
94. Skoog W.A. Adams W.S. 1959 Plasmapheresis in a case of Waldenstrom's macroglobulinemia Clinical Research 7 96
95. Strauss S.J. Maharaj L. Stec J. Boral A. Trehu E. Schenkein D. Joel S.P. Lister T.A. 2004 Phase II clinical study of bortezomib (Velcade) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) Blood 104 389a
96. Tam C.S. Wolf M.M. Westerman D. Januszewicz E.H. Prince H.M. Seymour J.F. 2005 Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia Clinical Lymphoma and Myeloma 6 136 139
97. Tamburini J. Levy V. Chaleteix C. Fermand J.P. Delmer A. Stalniewicz L. Morel P. Dreyfus F. Grange M.J. Christian B. Choquet S. Leblond V. 2005 Fludarabine plus cyclophosphamide in Waldenstrom macroglobulinemia: results in 49 patients Leukemia 19 1831 1834
98. Thalhammer-Scherrer R. Geissler K. Schwarzinger I. Chott A. Gisslinger H. Knobl P. Lechner K. Jager U. 2000 Fludarabine therapy in Waldenstrom's macroglobulinemia Annals of Hematology 79 556 559
99. Tournilhac O. Leblond V. Tabrizi R. Gressin R. Senecal D. Milpied N. Cazin B. Divine M. Dreyfus B. Cahn J.Y. Pignon B. Desablens B. Perrier J.F. Bay J.O. Travade P. 2003 Transplantation in Waldenstrom's macroglobulinemia - the French experience Seminars in Oncology 30 291 296
100. Treon S.P. Agus T.B. Link B. Rodrigues G. Molina A. Lacy M.Q. Fisher D.C. Emmanouilides C. Richards A.I. Clark B. Lucas M.S. Schlossman R. Schenkein D. Lin B. Kimby E. Anderson K.C. Byrd J.C. 2001 CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia Journal of Immunotherapy 24 272 279
101. Treon S.P. Branagan A.R. Hunter Z. Santos D. Tournhilac O. Anderson K.C. 2004 Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia Annals of Oncology 15 1481 1483
102. Treon S.P. Emmanouilides C. Kimby E. Kelliher A. Preffer F. Branagan A.R. Anderson K.C. Frankel S.R. 2005 Extended rituximab therapy in Waldenström's macroglobulinemia Annals of Oncology 16 132 138
103. Tsai D.E. Maillard I. Downs L.H. Alavi A. Nasta S.D. Glatstein E. Schuster S.J. 2004 Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia Leukemia and Lymphoma 45 591 595
104. Ueda T. Hatanaka K. Kosugi S. Kishino B.I. Tamaki T. 2001 Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinaemia with severe pancytopenia Bone Marrow Transplantation 28 609 611
105. Vela-Ojeda J. Garcia-Ruiz Esparza M.A. Padilla-Gonzalez Y. Rosas-Cabral A. Garcia-Chavez J. Xolotl-Castillo M. Salazar-Exaire D. Arenas-Osuna J. Avina-Zubieta J.A. Vadillo-Buenfil M. Abraham-Majluf S. 2002 IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenstrom's macroglobulinemia Journal of Interferon and Cytokine Research 22 1013 1016
106. Weber D.M. Dimopoulos M.A. Delasalle K. Rankin K. Gavino M. Alexanian R. 2003 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia Seminars in Oncology 30 243 247
107. Weber D.M. Delasalle K. Gavino M. Alexanian R. 2004 2- chlorodeoxyadenosine (2-CdA) and cyclophosphamide (Cy) alone or in combination with rituximab (Rit) for previously untreated Waldenstrom's macroglobulinemia (WM) Blood 104 413a
108. Weide R. Haymanns J. Koppler H. 2000 The polyneuropathy associated with Waldenström's macroglobulinemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab British Journal of Haematology 109 838 841
109. Yang L. Wen B. Li H. Yang M. Jin Y. Yang S. Tao J. 1999 Autologous peripheral stem cell transplantation for Waldenstrom's macroglobulinaemia Bone Marrow Transplantation 24 929 930
110. Zinzani P.L. Gherlinzoni F. Bendandi M. Zaccaria A. Aitini E. Salvucci M. Tura S. 1995 Fludarabine treatment in resistant Waldenström's macroglobulinemia European Journal of Haematology 54 120 123